Latest Articles in torrent pharmaceuticals
USFDA Inspects Torrent's Bileshwarpura Facility, Issues 'Form 483'
Ahmedabad-based Torrent Pharmaceuticals on Friday informed that the USFDA inspected its oral oncology manufacturing plant at Bileshwarpura, Gujarat from March 13th to March 17th, the pharmaceutical company said in a regulatory filing
Read More
Torrent Pharma's Net Profit Surges 14% YoY In Q3FY23
Torrent Pharmaceuticals, the Indian pharma major headquartered in Ahmedabad on Wednesday announced its consolidated financial results for the third quarter that ended 31st December 2022, the pharmaceutical company registered a 18 per cent rise in its consolidated revenues year on year
Read More
Torrent Pharma's Gujarat Facility Gets OAI Status From USFDA
The manufacturing site was first inspected on September 28, 2022, and was issued Form 483 with three observations by the top US Health regulator flagging quality as well as procedural lapses at the facility
Read More
Torrent Pharma Partners With Boehringer Ingelheim To Co-market Its Anti-diabetic Drug
Torrent Pharmaceuticals has entered into a strategic alliance with Boehringer Ingelheim India to co-market Cospiaq, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type
Read More
Torrent Pharma Reports Sales Of Rs 2,291 Cr, PAT Down By 1% YoY In Sept Quarter
The pharma company’s net profit slumped by 1 per cent year on year (YoY) and stood at Rs 312 crores in the second quarter from Rs 316 crores in the previous year
Read More
Torrent Pharma Registers Net Profit of 354 Cr Up By 7% For the June Quarter
The net sales rose to Rs 2,292 crore in the first quarter against Rs 2,120 crore in the year-ago period, Torrent Pharma said in a statement
Read More
Torrent Pharma Acquires 4 Brands From Dr. Reddy’s Laboratories
Styptovit-E, a gynaecology product with an estimated market size of Rs 500 crores (AIOCD data set), will further strengthen Torrent’s presence in the therapy. The acquisition of "Finast", "Finast-T", and "Dynapress", which are used in the treatment of Benign Prostatic Hyperplasia (BPH), will aid in
Read More